Table 4 Associations between CYP2J2 genotype combinations and with the risk of essential hypertension

From: A comprehensive study revealed SNP–SNP interactions and a sex-dependent relationship between polymorphisms of the CYP2J2 gene and hypertension risk

№

Genotype combinations

Healthy controls, N (%)a

EH patients, N (%)a

P-value

Q-value

adjOR (95% CI)b

Females (425 cases, 280 controls)

1

rs11572182TT/rs890293GT

16 (6.5)

51 (14.2)

0.006

0.018

2.31 (1.30–4.19)

2

rs10493270GG/rs890293GT

19 (7.7)

57 (15.9)

0.005

0.016

2.20 (1.25–3.94)

3

rs2280275AA/rs890293GG

184 (75.7)

233 (65.1)

0.008

0.018

0.62(0.44–0.89)

4

rs2280275AG/rs890293GT

16 (6.6)

54 (15.1)

0.004

0.016

2.44 (1.32–4.65)

5

rs2280275AG / rs11572182TT

31 (11.2)

82 (19.3)

0.008

0.018

1.87 (1.20–2.92)

6

rs2280275AA/rs10493270GG

163 (58.8)

213 (50.2)

0.042

0.045

0.70 (0.54–0.97)

7

rs2280275AG/rs10493270GG

47 (17.0)

110 (25.9)

0.008

0.018

1.68(1.14–2.78)

8

rs2280275AG/rs1155002СС

31 (11.2)

69 (17.4)

0.047

0.047

1.64 (1.03–2.60)

9

rs7515289AC/rs890293GT

16 (6.5)

48 (13.4)

0.019

0.027

2.14 (1.17–3.97)

10

rs7515289AC/rs11572182TT

33 (11.8)

81 (19.1)

0.025

0.032

1.74 (1.12–2.72)

11

rs7515289AC/rs2280275AG

43 (15.5)

108 (25.5)

0.003

0.016

1.83 (1.23–2.76)

12

rs11572325АА/rs890293GG

209 (85)

258 (72.1)

0.0004

0.011

0.47 (0.31–0.71)

13

rs11572325АТ/rs890293GT

19 (7.7)

52 (14.5)

0.019

0.027

1.98 (1.14–3.58)

14

rs11572325АТ/rs11572182TT

17 (6.1)

51 (12.0)

0.021

0.028

2.03 (1.16–3.67)

15

rs11572325АА/rs11572182GT

61 (21.8)

65 (15.3)

0.042

0.045

0.66 (0.45–0.97)

16

rs11572325АА/rs10493270GG

189 (67.5)

247 (58.3)

0.019

0.027

0.69 (0.51–0.94)

17

rs11572325АТ/rs10493270GG

27 (9.6)

83 (19.6)

0.0009

0.012

2.24 (1.40–3.59)

18

rs11572325АТ/rs1155002СТ

13 (4.7)

39 (9.8)

0.026

0.032

2.17 (1.14–4.14)

19

rs11572325АА / rs2280275AA

214 (77.3)

281 (66.4)

0.005

0.016

0.59 (0.43–0.86)

20

rs11572325АТ/rs2280275AG

31 (11.2)

83 (19.6)

0.005

0.016

1.90 (1.20–3.02)

21

rs11572325АТ/rs7515289AC

27 (9.6)

71 (16.8)

0.013

0.023

1.86 (1.15–2.97)

22

rs10889162GG//rs890293GG

213 (87.3)

280 (78.7)

0.012

0.023

0.55 (0.35–0.86)

23

rs10889162GA/rs890293GT

22 (9.0)

56 (15.7)

0.028

0.032

1.84 (1.09–3.04)

24

rs10889162GG/rs2280275AA

211 (76.7)

278 (66.2)

0.005

0.016

0.62 (0.44–0.85)

25

rs10889162GA/rs2280275AG

24 (8.7)

60 (14.3)

0.044

0.045

1.70 (1.03–2.80)

26

rs10889162GG/rs11572325АА

229 (82.4)

312 (74.1)

0.017

0.027

0.63 (0.43–0.95)

27

rs10889162GA/rs11572325АТ

19 (6.8)

57 (13.5)

0.009

0.018

2.02 (1.20–3.62)

Males (488 cases, 365 controls)

1

rs1155002ТТ/rs10493270GG

33 (9.1)

60 (14.3)

0.040

0.045

1.64 (1.04–2.56)

2

rs2280275AA/rs1155002ТТ

33 (9.1)

60 (14.3)

0.042

0.045

1.64 (1.04–2.56)

3

rs11572325АА/rs1155002ТТ

33 (9.1)

59 (14.1)

0.045

0.045

1.63 (1.03–2.55)

4

rs10889162GG/rs1155002ТТ

33 (9.2)

59 (14.7)

0.038

0.045

1.66 (1.05–2.62)

  1. Q-values at ≤  0.05 mean statistically significant associations after adjustment for multiple tests by the FDR method
  2. aAbsolute number and percentage of individuals with particular genotype combination
  3. bOdds ratio with 95% confidence intervals adjusted for age and BMI
Back to article page